Your session is about to expire
← Back to Search
Local Analgesic
Bupivacaine-Meloxicam for Surgical Incisions
Phase 3
Recruiting
Research Sponsored by TriHealth Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
English as first language
Undergoing retropubic mid-urethral sling surgery (with concomitant anterior repair or urethrocele repair)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 72 hours post surgery
Awards & highlights
Study Summary
This trial compares local anesthetics and painkillers to see if they reduce pain and narcotic use during surgery.
Who is the study for?
This trial is for English-speaking patients having retropubic mid-urethral sling surgery, possibly with anterior or urethrocele repair. It's not for those getting additional surgeries like hysterectomy, can't consent, are allergic to the study drugs, pregnant/breastfeeding, recently used steroids or various painkillers.Check my eligibility
What is being tested?
The study tests a combined local anesthetic (Bupivacaine-meloxicam) on abdominal incisions in sling surgery patients. It aims to see if this reduces the need for narcotics and lessens pain compared to current practices.See study design
What are the potential side effects?
Potential side effects may include reactions at the injection site such as swelling or itching, possible nerve damage risks associated with injections near nerves, and typical drug-related issues like nausea or headaches.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
English is my first language.
Select...
I am having surgery to support my bladder or urethra.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 72 hours post surgery
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~72 hours post surgery
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
To determine if use of bupivacaine-meloxicam reduces post-operative narcotic use over the first 3 days following surgery
Secondary outcome measures
Compare average pain on each day post operatively
Compare satisfaction with pain control post operatively
Compare worst pain on each day post operatively
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: bupivacaine-meloxicamExperimental Treatment1 Intervention
All patients will receive a total of 20 cc lidocaine with epinephrine injection intra-operatively along the trocar path via the suprapubic incisions, as is standard practice to help with hydrodissection for the procedure. 3-4 cc of bupivacaine-meloxicam will be infiltrated into each suprapubic abdominal incision in the study group
Group II: Standard of CareActive Control1 Intervention
All patients will receive a total of 20 cc lidocaine with epinephrine injection intra-operatively along the trocar path via the suprapubic incisions, as is standard practice to help with hydrodissection for the procedure.
Find a Location
Who is running the clinical trial?
TriHealth Inc.Lead Sponsor
97 Previous Clinical Trials
53,462 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- English is my first language.I haven't taken long-acting opioids in the last 3 days.I have not taken steroids in the last 10 days.You have been taking opioid pain medication every day for the past 3 months.I have not taken any opioids in the last 24 hours.I am unable to give consent for my own medical treatment.You are allergic to meloxicam or bupivacaine.I haven't taken NSAIDs in the week before my surgery.I am having surgery to support my bladder or urethra.I am having or have had surgery for pelvic organ prolapse or related conditions.
Research Study Groups:
This trial has the following groups:- Group 1: bupivacaine-meloxicam
- Group 2: Standard of Care
Awards:
This trial has 2 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Has bupivacaine-meloxicam been accepted by the FDA?
"The safety profile of bupivacaine-meloxicam was rated a 3 by the Power team, due to pre-existing clinical data that demonstrated its efficacy and robust evidence in favour of its security."
Answered by AI
Could you kindly provide information on the availability of enrollment in this investigation?
"According to clinicaltrials.gov, this research endeavour is no longer recruiting patients - it was initially posted on January 1st 2023 and last updated 18 days later. Nonetheless, there are currently 221 other trials seeking participants for their studies."
Answered by AI
Who else is applying?
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
What site did they apply to?
Trihealth (Good Samaritan Hospital, Bethesda North Hospital)
What questions have other patients asked about this trial?
What kind of Side Effects??
PatientReceived 1 prior treatment
Why did patients apply to this trial?
Seems like non of the Doctors in my area have very much research on the matter.
PatientReceived 2+ prior treatments
Share this study with friends
Copy Link
Messenger